Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took a dose of Vivotif that was approximately 24 hours early, rather than having that 48-hour gap or two-day gap; Case reference number US-BN-2025-001107 is a spontaneous case initially received from a pharmacist via Communications (reference number: USBAV25-1483) on 20-Jun-2025 and concerns male patient of unspecified age. The patient's concomitant medications and historic conditions were not provided. On an unspecified age, the patient took first dose of Vivotif, (batch number: unknown) orally for an unknown indication. On an unspecified age, unknown amount of time after first dose, the patient took second dose of Vivotif, (batch number: unknown) orally. On an unspecified age, unknown amount of time after second dose, the patient took third dose of Vivotif, (batch number: unknown) orally. On an unspecified age, unknown amount of time after third dose, the patient took fourth dose of Vivotif, (batch number: unknown) orally. The patient took one dose of the vaccine approximately 24 hours early, rather than adhering to the recommended 48-hour (two-day) interval. It is unclear whether this was the second or third dose, but it was confirmed with the healthcare provider that the patient completed the full course of four capsules. Only one dose was taken too early (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. No further information reported.; Reporter's Comments: A male patient of unspecified age took one dose of Vivotif vaccine approximately 24 hours early, rather than adhering to the recommended 48-hour (two-day) interval, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's concomitant medications and historic conditions were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age took one dose of Vivotif vaccine approximately 24 hours early, rather than adhering to the recommended 48-hour (two-day) interval, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's concomitant medications and historic conditions were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.